Frontlight ResearchEarly access
Enrolling by invitationNo phase
Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)
Key facts
- Who runs it
- Lancaster General Hospital
- Where
- Lancaster, United StatesSee the site
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 225 people, planned
- Started
- 1 Dec 2023
- Expected to end
- Nov 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Repeat Thromboelastography with Platelet Mapping
- Record updated
- 29 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients ≥ 18 years of age who present with TICH meeting Brain Injury Guidelines (BIG) 2 or 3 head bleed criteria
- Currently on antiplatelet medication on admission
- Must have taken this antiplatelet medication within the past 48 hours prior to presentation
- Patients who have AA and/or ADP inhibition of 70% or greater and Maximum Amplitude (MA) <50 will then receive a platelet transfusion and a repeat TEG-PM 1hr after transfusion
- Patients with a TICH who are 18 years of age or older
Who cannot take part
- Do not know the time of their last antiplatelet medication dose
- Patients with concomitant long bone fractures or solid organ injuries
- Abbreviated Injury Scale (AIS) >1 in body regions other than head because of concomitant long bone fracture or solid organ injury
- Have a known bleeding diatheses
- Under 18 years of age
- Under 18 years of age
- Current therapeutic anticoagulation use
- Patients or their proxy who are unable to provide consent
Where in United States
- Penn Medicine Lancaster General HealthLancaster, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The aim of this study is to see if administering platelets (cells in our blood that stop or prevent bleeding) results in improved platelet function and slows/stops the progression of a head bleed for patients who have a traumatic head bleed and are on antiplatelet therapy (medications that stop blood cells from forming a blood clot) prior to admission.
The 2 groups in the trial
- Repeat TEG-PM
Will receive a repeat TEG-PM after platelet transfusion based on inclusion criteria.
Treatment: Repeat Thromboelastography with Platelet Mapping
- No Repeat TEG-PM
Not eligible to be consented; will proceed with normal course of treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Platelet Transfusion and Repeat Thromboelastography With Platelet Mapping (TEG-PM) in Patients With Severe Traumatic Brain Injuries (TBI) on Antiplatelet Therapy
- Record updated
- 29 October 2025